Business concept and strategy

Vision

Improving life for cancer patients through transformative drugs.

The story of Medivir

Medivir was founded in 1988 and has been a publicly listed since 1996 on Nasdaq Stockholm. The company has developed two pharmaceutical products, Xerclear and Olysio, all the way from idea to market launch. In the same time, the company has ventured into more than 20 partnership agreements, often with repeat partners, that together have generated more than 400 million USD in revenues to the company. Late 2018, the company focused its resources to its clinical development projects within oncology.

Medivir develops innovative pharmaceuticals for the treatment of cancer. The focus is on cancers of high unmet medical need, where existing therapies are limited or missing, and there is a great opportunity to provide real benefit to patients. Collaborations and partnerships are important components of Medivir’s business model, and the drug development as well as the commercialization process is conducted either on its own or in partnership.

Business model

Medivir conducts clinical development in order to on its own, or through partnerships or out-licensing agreements, bring its candidate drugs to market approval. Our specialist capabilities encompass various areas, including patent strategy, drug development, clinical trial design, regulatory affairs and business development. Medivir leverages its collaborations with academic, health care and industrial partners to bring their unique knowledge and experience to our projects.

Medivir intends to maximize the value of each project. For commercialization of a specialist drug, the company may choose to market the product on its own in certain territories, when the number of prescribers is limited. For medicines with larger patient groups and greater market potential, Medivir intends to seek commercial partners before entering phase III in order to ensure the fastest route to the market and the commercial strength needed to launch and market the product.

Strategic priorities

Medivir has three overall strategic priorities. They are based on our leading development expertise and proven business development capabilities.

  1. To persevere in driving candidate drugs through clinical development in a highly efficient way
    Develop and nurture meaningful and mutually beneficial partnerships in order to accelerate the clinical development and to spread financial risks.
  2. To be a respected partner and generate revenue through partnerships
    Develop and nurture meaningful and mutually beneficial partnerships in order to accelerate the clinical development and to spread financial risks.

  3. To continuously develop an inspiring corporate culture based on business experience, professionalism, collaborative skills and creativity
    Cultivate a creative, inspiring and professional corporate culture that strengthens our ability to work more virtual.